Babalola Ooreofe Feranmi
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Babalola Ooreofe Feranmi has a total of 14 co-authors. Here are the top co-authors by number of shared publications:
Aghogho Oyibo
Christland University
1 shared publicationAyomide Oluwaseun Adereti
University of Nigeria
1 shared publication- Ezekiel Musa
Department of Internal Medicine, Kaduna State University, Nigeria
1 shared publication Fabrice Banadzem Kernyuy
Covenant University
1 shared publicationGlory Chinuru Musa
Independent Researcher
1 shared publicationIsrael Ogwuche Ogra
UNESCO International Centre for Biotechnology
1 shared publication
Latest Publications
- Open Access
- 12 November 2026
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 21 (11) , e0361047
Anti-inflammatory effects of metformin in gestational diabetes: Systematic review and meta-analysis of randomized trials and preclinical animal pregnancy models study protocol
Background: Gestational diabetes mellitus (GDM) is a significant complication that can occur during pregnancy. It is characterized by glucose intolerance that first arises during pregnancy and is associated with insulin resistance, which is linked to elevated inflammatory markers. Metformin has emerged as a promising treatment option for GDM, with growing evidence supporting its anti-inflammatory effects. These effects are thought to be mediated by activation of AMP-activated protein kinase (AMPK) and inhibition of NF-κB signaling. This systematic review aims to assess the anti-inflammatory effects of metformin in GDM, considering both clinical and preclinical studies. Methods: A systematic review of all randomized controlled trials and controlled in vivo experiments for animals published until 2026 will be carried out. A comprehensive search of all published articles indexed in PubMed/MEDLINE, the Cochrane Library, Scopus, CINAHL (EBSCOhost), Embase, and Web of Science will be performed. Studies will be screened for eligibility by title, abstract, and full text in duplicate by two independent reviewers. For data where meta-analysis is not possible, a narrative analysis will be conducted using themes derived from the data. For data that allow meta-analysis, a random-effects meta-analysis will be conducted. This systematic review will be reported in accordance with the Preferred Reporting Items for Systematic Reviews and Meta-Analysis (PRISMA). Discussion: The study will utilize meta-analysis to establish the anti-inflammatory effects of metformin in GDM, potentially influencing clinical practice and guidelines. Additionally, validating metformin’s anti-inflammatory effects has important implications beyond immediate management of GDM, extending to long-term adverse outcomes for both the mother and the offspring. Systematic review registration: PROSPERO CRD420261337881
- 12 November 2026
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 21 (11) , e0361047
Open AccessAnti-inflammatory effects of metformin in gestational diabetes: Systematic review and meta-analysis of randomized trials and preclinical animal pregnancy models study protocol
Background: Gestational diabetes mellitus (GDM) is a significant complication that can occur during pregnancy. It is characterized by glucose intolerance that first arises during pregnancy and is associated with insulin resistance, which is linked to elevated inflammatory markers. Metformin has emerged as a promising treatment option for GDM, with growing evidence supporting its anti-inflammatory effects. These effects are thought to be mediated by activation of AMP-activated protein kinase (AMPK) and inhibition of NF-κB signaling. This systematic review aims to assess the anti-inflammatory effects of metformin in GDM, considering both clinical and preclinical studies. Methods: A systematic review of all randomized controlled trials and controlled in vivo experiments for animals published until 2026 will be carried out. A comprehensive search of all published articles indexed in PubMed/MEDLINE, the Cochrane Library, Scopus, CINAHL (EBSCOhost), Embase, and Web of Science will be performed. Studies will be screened for eligibility by title, abstract, and full text in duplicate by two independent reviewers. For data where meta-analysis is not possible, a narrative analysis will be conducted using themes derived from the data. For data that allow meta-analysis, a random-effects meta-analysis will be conducted. This systematic review will be reported in accordance with the Preferred Reporting Items for Systematic Reviews and Meta-Analysis (PRISMA). Discussion: The study will utilize meta-analysis to establish the anti-inflammatory effects of metformin in GDM, potentially influencing clinical practice and guidelines. Additionally, validating metformin’s anti-inflammatory effects has important implications beyond immediate management of GDM, extending to long-term adverse outcomes for both the mother and the offspring. Systematic review registration: PROSPERO CRD420261337881